EMYRIA LIMITED — Capital/Financing Update 2020

Nov 1, 2020

ASX/Media Release

==> picture [116 x 62] intentionally omitted <==

01/11/2020

Emyria receives $954,180 R&D tax incentive refund

Highlights:

• Emyria receives R&D Tax Incentive refund of A$954,180

• Funds will be invested into accelerating the commercialisation of Emyria’s Data Products, technologies and supporting internal data analysis

• Emyria well positioned to deliver leading care, digital health and data products to patients globally

Emyria Limited (ASX: EMD) (Emyria or the Company), a company that develops and commercialises clinical technologies and data products and also manages an Australia-wide clinical service for patients with unmet medical needs (Emerald Clinics), is pleased to announce that it has received a Research and Development (R&D) Tax Incentive refund of A$954,180 for the financial year 2019/2020.

Emyria Managing Director Dr Michael Winlo said: “ Combined with the recent capital raising, the receipt of the R&D tax incentive refund further strengthens our capital position and enables us to accelerate our growth plans across our business to deliver significant shareholder value.”

The R&D Tax Incentive is an Australian Government program to support Australian companies to undertake R&D activities in Australia, under which eligible companies can receive cash rebates of up to 43.5% of eligible expenditure on R&D activities.

From the funds received, the Company has repaid the $259,638 drawn under its R&D credit facility with Radium Capital. The balance of the funds received will be invested into accelerating the commercialisation of Emyria’s Data Products, technologies and supporting internal data analysis.

Release authorised by: Michael Winlo Managing Director

For further information

Dr Michael Winlo Jane Morgan CEO Media/Investor Relations (08) 6559 2800 + 61 (0) 405 555 618 mwinlo@emyria.com jm@janemorganmanagement.com.au

About Emyria (www.emyria.com)

Emyria Limited creates data products from robust and ethically sourced Real-World Evidence (RWE) gathered across its specialist clinical network - Emerald Clinics (www.emeraldclinics.com.au). Emyria’s data products – Emyria Registration and Emyria Pharmacovigilance - accelerate the development and registration of new and promising treatments for patients with unmet medical needs by providing unique, real-world insights into treatment safety, quality and efficacy. Emyria’s data assets are also a source of unique IP for Emyria. In addition, Emyria creates remote patient monitoring technologies, data platforms and care models that further improve the quality of its RWE data assets and insights.

==> picture [592 x 44] intentionally omitted <==

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forwardlooking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.